Watchlist

Watchlist
Acceleron Pharma Inc. (XLRN)
Acceleron Pharma Inc. (XLRN)
Acceleron's (XLRN) Acceleron ASH 2017 Update Conference (Transcript)
Acceleron, Pharma Inc. (XLRN) Acceleron ASH 2017 Update Conference Call December 11, 2017 08:00 AM ET Executives Todd James - VP, IR and Corporate Communications Habib Dable - CEO Matthew Sherman - Chief Medical Officer Analysts Kripa Krishnamoorthy - Citigroup Jeff Hung …
Cutting Edge Gene Therapies: Beta-Thalassemia Breakthroughs (Part I)
Investment Thesis and Topic: There have been many gene therapy companies which have arisen over the past decade to treat beta-thalassemia. This devastating illness results in very high lifetime costs (upwards of $1 million) and an estimated 60,000 patients which currently have a complicated …
Acceleron Pharma (XLRN) ASH 2017 Phase 2 Presentation Highlights - Slideshow
The following slide deck was published by Acceleron Pharma Inc. in conjunction with this Read more …
Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology
- Preliminary results show treatment with luspatercept increases hemoglobin and achieves durable red blood cell transfusion independence in patients with lower-risk myelodysplastic syndromes - - Conference call and webcast to be held on Monday, December 11 th at 7:00 a.m. EST - …
Biotech Forum Daily Digest: Our Take On MiMedx
Today's public figures can no longer write their own speeches or books, and there is some evidence that they can't read them either . - Gore Vidal The biotech sector had a decent performance in the previous week as the overall market drifted up powered by strong economic reading…
Acceleron to Host Conference Call and Webcast to Review Data Presented at the 59th American Society of Hematology Annual Meeting and Exposition
Acceleron Pharma Inc. (NASDAQ:XLRN) will host a conference call and live audio webcast on Monday, December 11, 2017 at 7:00 a.m. EST to review highlights from its Phase 2 clinical presentations at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition taking place Decemb…
Stocks to watch next week
Key events are scheduled for the companies listed below next week. More news on: Palo Alto Networks, Urban Outfitters, Inc., Dollar Tree, Inc., Consumer stocks news, Tech stocks news, Healthcare stocks news, Read more …
Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire
Acceleron Pharma Inc. (NASDAQ:XLRN) today announced the appointment ofthe experienced biopharmaceutical executive, Karen Smith, M.D., Ph.D., to its board of directors and the departure of Terrance McGuire, effective November 15, 2017. Karens breadth of expertise in …
Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions
- Preclinical results show potential first-in-class disease-modifying properties of sotatercept in pulmonary arterial hypertension - - Company expects to initiate a Phase 2 trial in 1H 2018 - Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discover…
Acceleron Pharma's (XLRN) CEO Habib Dable on Q3 2017 Results - Earnings Call Transcript
Acceleron Pharma Inc. (XLRN) Q3 2017 Earnings Conference Call November 07, 2017 08:00 AM ET Executives Todd James - Vice President, Investor Relations and Corporate Communication Habib Dable - Chief Executive Officer Matthew Sherman - Chief Medical Officer Kevin McLaughlin - Ch…
The Stumbling Blocks Of Celgene-Dependent Acceleron And Why You Should Hedge Your Bets
Introduction Acceleron Pharma Inc. (NASDAQ: XLRN ), formerly known as Phoenix Pharma, Inc., is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. The Company is focused on the discovery, development, and commercialization of therapeutics to treat cancer and rare …
Acceleron Pharma Inc. (XLRN)